A Novel ESRRB Deletion Is a Rare Cause of Autosomal Recessive Nonsyndromic Hearing Impairment among Pakistani Families by Lee, Kwanghyuk et al.
SAGE-Hindawi Access to Research
Genetics Research International
Volume 2011, Article ID 368915, 4 pages
doi:10.4061/2011/368915
Research Article
AN o v elESRRB Deletion Isa Rare Cause of Autosomal Recessive
NonsyndromicHearing Impairmentamong Pakistani Families
Kwanghyuk Lee,1 SaadullahKhan,2 Muhammad Ansar,2 Regie Lyn P. Santos-Cortez,1
Wasim Ahmad,2 andSuzanneM. Leal1
1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Tx 77030, USA
2Department of Biochemistry, Faculty of Biological Sciences, Quaid-I-Azam University, Islamabad 45320, Pakistan
Correspondence should be addressed to Suzanne M. Leal, sleal@bcm.edu
Received 30 May 2011; Accepted 1 August 2011
Academic Editor: Karen Friderici
Copyright © 2011 Kwanghyuk Lee et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Mutationsintheestrogen-relatedreceptorbeta(ESRRB)geneistheunderlyingcauseofautosomalrecessivenonsyndromichearing
impairment (ARNSHI) due to the DFNB35 locus which maps to 14q24.3. A genome scan of a large consanguineous Pakistani
pedigree with ARNSHI established linkage with a maximum multipoint LOD score of 4.2 to the 14q24 region and the region
of homozygosity contained the ESRRB gene. Sequencing of the ESRRB gene using DNA samples from hearing-impaired family
members uncovered a novel three-nucleotide deletion c.1018 1020delGAG (p.Glu340del). The deletion segregates with hearing
impairment in the pedigree and was not observed in 500 control chromosomes. The deletion of glutamic acid residue occurs in
the ligand-binding domain of ESRRB protein. It is expected that the deletion aﬀects the ligand-binding activity of the domain in
ESRRB, which leads to the ARNSHI.
1.Introduction
Hearing impairment (HI) has been associated with estro-
gen physiology for decades. Turner’s syndrome in females
and Noonan’s syndrome in males are both marked by
hypoestrinism and include the HI phenotype. Variations in
hearing function have also been found according to gender,
menstrual cycle or menopausal state, estrogen therapy, and
oralcontraceptiveuse,whichimplicate estrogenasaprimary
requirement for hearing preservation [1]. Recently, autoso-
mal recessive nonsyndromic hearing impairment (ARNSHI)
locus DFNB35 was shown to be due to mutations in
the estrogen-related receptor beta or ESRRB gene (MIM
602167; 2). ESRRB belongs to a subfamily of orphan nuclear
receptors that are structurally related to estrogen receptors
(ER) but do not directly bind estrogen. The ESRR proteins
have DNA-binding and ligand-binding domains, which are
both required for transcriptional regulation of ER target
genes.Theligand-bindingdomain(LBD)providesstructural
stability and inﬂuences the binding aﬃnity of the ESRRB
protein [2]. Here, we report a novel deletion mutation of
glutamic acid residue in LBD domain of ESRRB gene which
is responsible for ARNSHI.
2.MaterialandMethods
The study was approved by the Institutional Review Boards
of the Quaid-I-Azam University and the Baylor College
of Medicine and Aﬃliated Hospitals prior to initiation.
Informed consent was obtained from all members from
family 4243 who participated in the study. Family 4243
(Figure 1) is a consanguineous kindred from the Sairiki-
speaking region of Punjab, Pakistan. The family segregates
ARNSHI of prelingual onset and has no history of environ-
mental exposure to factors that may cause HI, for example,
infection, ototoxic medication, and trauma. Syndromic and
vestibular features were ruled out through careful physical
examination. To determine the severity of HI, air conduction
testing was performed using a portable audiometer.2 Genetics Research International
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Figure 1: Pedigree drawing of family 4243. Filled symbols represent individuals with ARNSHI, and clear symbols represent hearing
individuals. Displayed under each individual are the SNP markers within the region of the ESRRB gene and the p.Glu340del mutation.
The haplotype segregating with the ARNSHI phenotype is shown within a box. The homozygous region that is found only in ARNSHI
individuals is bounded by rs917284 (chr14:71.8Mb) and rs2043585 (chr14:79.0Mb). The black arrow indicates the position of ESRRB
gene amid the SNP marker loci.
Genomic DNA was extracted from venous blood which
was provided by ﬁve hearing and four HI family members
(Figure 1). The nine DNA samples from this family under-
wentawholegenomelinkagescanattheCenterforInherited
Disease Research (CIDR) using the Illumina Linkage Panel
IV-bwhichcontains6,090SNPmarkers.Dataqualitycontrol
was performed using PedCheck [3] to check for genotyping
error which resulted in Mendelian inconsistencies, while
MERLIN [4] was used to detect occurrence of double
recombination events over short genetic distances, which
are most likely due to genotyping error. Two-point linkage
analysis was carried out using MLINK of the FASTLINK
package [5], and multipoint linkage analysis was performed
with Allegro [6], while haplotypes were reconstructed using
SimWalk2 [7]. An autosomal recessive mode of inheritance
with complete penetrance and a disease allele frequency of
0.001 were used in the analysis. Marker allele frequencies
were estimated from observed and reconstructed founders
from family 4243 and 73 additional families who underwent
genome scan at the same time at CIDR. For the multipoint
linkage analysis, genetic map positions were determined
according to the Rutgers combined linkage-physical map of
the human genome [8] using the human reference sequence
(Build 36) to determine the physical map position, and then,
interpolation was performed to place the markers on the
Rutgers map.
Exon primers for ESRRB (RefSeq NM 004452.3) gene
were designed using Primer3 software [9]. PCR-ampliﬁed
products were puriﬁed with ExoSAP-IT (USB Corp., Cleve-
land, Ohio, USA) and sequenced with the BigDye Ter-
minator v3.1 Cycle Sequencing Kit and the ABI 3730
DNA Analyzer (Applied Biosystems Inc, Foster City, Calif,
USA). Sequencher software V4.9 (Gene Codes Corp., Ann
Arborich, USA, M) was used to assemble and analyze DNA
sequences.
3. Results and Discussion
The audiogram of HI individual IV-4 displays bilateral,
severe-to-profound HI aﬀecting all frequencies (Figure 2).
Thisisconsistentwiththepreviousdescriptionofprelingual,
bilateral profound hearing loss across all frequencies for
ESRRB-related HI [2].
For family 4243, a maximum two-point LOD score of
3.04 (θ = 0) was observed at marker rs935340 (chr14:
75.66Mb; see Table 1). A signiﬁcant maximum multipointGenetics Research International 3
Table 1: Two-point and multipoint LOD scores for family 4243.
Marker name1 Physical map
position2
Genetic map
position3
Multipoint
LOD score
Two-point LOD score at θ =
0.00 0.01 0.05 0.10 0.20 0.30
rs221924 70,650,531 66.96 −4.52 −2.02 −0.26 0.28 0.39 0.33 0.20
rs917284 71,806,864 67.80 −2.56 −1.41 0.34 0.84 0.90 0.70 0.36
rs1468507 73,641,851 70.09 4.15 2.67 2.62 2.40 2.12 1.54 0.94
rs935340 75,660,959 72.79 4.16 3.04 2.98 2.72 2.40 1.73 1.06
rs888412 77,676,577 75.73 4.16 1.34 1.30 1.13 0.91 0.46 0.02
rs2043585 79,039,998 77.88 −17.85 −∞ 0.58 1.08 1.13 0.92 0.56
rs1530771 80,095,275 78.71 −∞ −∞ 0.47 0.98 1.04 0.84 0.50
rs799032 81,707,098 79.67 −∞ −∞ 0.84 1.32 1.35 1.09 0.69
rs1964413 82,338,459 80.75 −1.27 2.08 2.04 1.88 1.66 1.22 0.76
rs1885316 84,924,908 82.25 −6.89 −2.37 −0.60 −0.03 0.12 0.15 0.09
rs1956411 88,204,113 85.49 −5.94 −2.10 −0.33 0.22 0.36 0.34 0.22
1Markers in bold denote marker limits based on 3-unit support interval and homozygous region.
2Physical map positions from Build 36.1 of human reference sequence.
3Genetic map positions based on Rutgers linkage physical map of the human genome.
LOD score of 4.16 was obtained at two marker loci, rs935340
and rs888412 (77.68Mb). The 3-unit support interval and
the region of homozygosity that was observed only in HI
individuals (Table 1; Figure 1) fall between markers rs917284
(71.81Mb) and rs2043585 (79.04Mb). The linkage region
spans 10.08cM within 14q24.2–q31.1 and contains 7.23Mb
of sequence. A total of 83 genes are found within the linkage
interval, including the known ARNSHI gene, ESRRB. Since
variants within the ESRRB gene are known to be involved in
NSHI [2], the exon regions of ESRRB gene were sequenced.
Sequencing of the ESRRB gene in family 4243 revealed
a novel deletion c.1018 1020delGAG (p.Glu340del) in exon
8 which segregates with ARNSHI (Figure 1). The deletion
wasnotannotatedinthedbSNPdatabaseand1000Genomes
project. Additionally, exon 8 of ESRRB was sequenced in 250
unrelatedhearingindividualsfromPakistan;thedeletionwas
not found in 500 control chromosomes.
The glutamic acid residue at position 340 is the second
residue within α-helix 8 at the LBD of the ESRRB protein.
In order to form a hypothesis on the eﬀect of its deletion
to protein structure, ESRRB-like proteins from both human
and nonhuman species were identiﬁed from the UniProt
Knowledgebase [10] using blastp [11] and aligned via
ClustalW [12]. The Glu340 residue is invariant for ESRRB
and other steroid receptor proteins in 39 nonhuman species,
including 7 mammalian, 1 avian, 2 reptilian, 3 amphibian,
17 ﬁsh, 2 ascidian, 3 mollusk, and 4 arthropod. It is also
conserved in 32 human nuclear receptor proteins, which
indicates that this residue is essential to the structure of
the LBD. Using the SWISS-MODEL Workspace [13], the
LBD of ESRRB was modeled after the LBD of human
proteins ESRRG (PDB ID: 2GPO) [14] and PPARG (PDB
ID: 3DZY) [15]. The Glu340 residue forms a hydrogen bond
with Glu337, the last of three residues of the α-α corner
between α-helices 7 and 8. This hydrogen bond marks the
beginning of the formation of α-helix 8. Glu340 also forms
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Figure 2: Audiogram of individual IV-4 demonstrates bilateral
severe-to-profound HI at all frequencies. Air conduction threshold
testing was performed for the right (circles) and left (crosses) ears.
two hydrogen bonds with Arg388, the ﬁrst residue of α-helix
10. Removal of Glu340 dissolves these hydrogen bonds and
also results in the rotation of the side chains of residues
336–339 along the helical axis. Residues at positions 336–
340 do not have direct contact with ligand. However, the
removalofhydrogenbondsduetop.Glu340delisexpectedto
aﬀect the stability of α-helix 8 and its conformation relative
to other helices, in particular α-helices 7 and 10. Notably,
the side chain of Lys338 is moved out of the hydrophobic
pocket formed by Leu286, Tyr290, Tyr331, and Phe341.
In the known crystal structure of the LBD of ESRRG, a
similar pocket is contiguous with the second pocket of the
LBD, which receives agonist ligand GSK4716 and coactivator4 Genetics Research International
RIP140 [14]. The ESRRG-RIP140 interaction is facilitated
by conformational changes in the charged residues on the
LBDsurface.The hydrophobic pocket which includes Lys338
of ESRRB may have a similar function of allowing agonist
ligand and coactivator binding by increasing the volume for
ligand interaction and providing charged residues that are
required for ligand binding.
Three of ﬁve reported ESRRB mutations that cause
ARNSHI are also predicted to result in structural defects at
the LBD [1]. In particular, two ESRRB mutations, namely,
p.Val342Leu and p.Leu347Pro [2], also occur within α-helix
8. Both substitutions are predicted to disrupt hydrophobic
interactions of α-helix 8 with other helices, thus resulting in
conformational change and decreased stability of the LBD
[2]. Mutations in α-helix 8 that decrease ligand-binding
aﬃnity have been identiﬁed in other nuclear receptor
proteins, ESR1 and HNF4α, which have structures similar
to ESRRB [16, 17]. The p.Glu276Gln mutation for HNF4α,
which is one of the underlying causes of mature-onset
diabetes in the young, results in unstable protein with no
DNA-binding ability and, hence, no transcriptional activity
[16] .T h eG l u 2 7 6r e s i d u eo fH N F 4 α aligns with Glu340 of
ESRRB. It is, therefore, highly plausible that p.Glu340del
aﬀects the stability and ligand-binding activity of the ESRRB
protein in order to result in the HI phenotype.
4. Conclusion
A genome-wide linkage scan performed using DNA samples
from a large consanguineous ARNSHI pedigree and the
subsequent sequencing of the ESRRB gene led to the iden-
tiﬁcation of a novel deletion mutation c.1018 1020delGAG
(p.Glu340del). The glutamic acid residue 340 is located
in the ligand-binding domain of the ESRRB protein. The
identiﬁcation of the deletion mutation of ESRRB gene will
expand our understanding of hearing impairment due to
mutations in the estrogen-related gene ESRRB.
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